Ipilimumab (anti-CTLA-4)

目录号：A2001         批次号: A200109

打印

Ipilimumab (anti-CTLA-4)是一种免疫调节单克隆抗体，靶向细胞表面抗原CTLA-4；也是一种免疫检查点抑制剂；MW：148 KD。

抗体信息

CAS号 477202-00-9
配制 PBS buffer, pH 7.2
推荐同型对照 Human IgG1
来源 CHO cells
储存条件
(自收到货起)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
除菌 0.2 μM filtered
纯度 99%
蛋白浓度 8.873mg/ml
内毒素 ＜1EU/mg

客户使用selleck产品的实验数据

Ipilimumab (anti-CTLA-4)在文献中得到引用

Role of the androgen receptor in melanoma aggressiveness [ Cell Death Dis, 2025, 16(1):34] PubMed: 39837817
Inhibition of C5a-C5aR1 axis suppresses tumour progression by enhancing antitumour immunity and chemotherapeutic effect in pancreatic ductal adenocarcinoma [ Br J Cancer, 2025, 10.1038/s41416-025-03185-0] PubMed: 41044172
Sprinkling in extra validation for high-value PTMs and therapeutic Abs with MILKSHAKE Western blots and Sundae ELISAs [ N Biotechnol, 2025, 89:11-19] PubMed: 40482963
Biofabrication of pheochromocytoma and paraganglioma tumor organoids and assessment of response to systemic therapy [ Sci Rep, 2025, 15(1):35889] PubMed: 41087622
Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy [ Cancer Cell, 2024, S1535-6108(24)00080-1] PubMed: 38518774
A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies [ Cells, 2023, 12(8)1145] PubMed: 37190054
A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies [ Cells, 2023, 12(8)1145] PubMed: 37190054
Cyclooxygenase-2 Blockade Is Crucial to Restore Natural Killer Cell Activity before Anti-CTLA-4 Therapy against High-Grade Serous Ovarian Cancer [ Cancers (Basel), 2023, 16(1)80] PubMed: 38201508
Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma [ Front Immunol, 2022, 13:925633] PubMed: 36091050
A Platform of Patient-Derived Microtumors Identifies Individual Treatment Responses and Therapeutic Vulnerabilities in Ovarian Cancer [ Cancers (Basel), 2022, 14(12)2895] PubMed: 35740561

禁止用于人体及治疗！